[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Mashita T, Shimoda T, Yoshioka H, Takahashi Y, Mitsuda M: A cat with acute myeloblastic leukemia without maturation (M1) treated with combination chemotherapy. J Vet Med Sci; 2006 Jan;68(1):97-101
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cat with acute myeloblastic leukemia without maturation (M1) treated with combination chemotherapy.
  • Acute myeloblastic leukemia without maturation (M1) was diagnosed according to the FAB classification.
  • Chemotherapy was initiated with cyclophosphamide, vincristine, prednisolone, and cytosine arabinoside.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462128.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


2. Dimicoli S, Fohlen-Walter A, Mansuy L, Buisine J, Grégoire MJ, Lecompte T, Bordigoni P, Jonveaux P, Lesesve JF: [Acute myeloblastic leukemia without maturation (AML-M1) with basophilic elements and associated with translocation t(6;9)]. Ann Biol Clin (Paris); 2003 May-Jun;61(3):352-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myeloblastic leukemia without maturation (AML-M1) with basophilic elements and associated with translocation t(6;9)].
  • [Transliterated title] Leucémie aiguë myéloblastique sans maturation (LAM1) avec éléments basophiles associée à la translocation t(6;9).
  • The clinical, hematological, and cytogenetic data from a 4 year-old child with acute myeloid (AML-M1) and basophilia is reported.
  • This abnormality is rare and associated with myelodysplastic syndromes or with subtypes of acute myeloid leukemia (M1, M2, M4, M7), usually with preceding or underlying myelodysplasia.
  • The prognosis is poor, without response to chemotherapy regimen alone.
  • Allogeneic bone marrow transplantation appears likely to be a more appropriate treatment.
  • [MeSH-major] Basophils. Chromosomes, Human, Pair 6 / genetics. Chromosomes, Human, Pair 9 / genetics. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12805015.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


3. Ogasawara T, Yasuyama M, Kawauchi K: Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Am J Hematol; 2005 Jun;79(2):136-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
  • We describe a patient who developed myelodysplastic syndrome over 2 years after achieving complete remission of acute myeloid leukemia (AML).
  • The patient was treated in July 1998 with anthracycline, etoposide, and behenoyl cytarabine chemotherapy for AML (French-American-British classification, M2; World Health Organization classification, AML with maturation) and achieved complete remission.
  • The pancytopenia progressed rapidly, and he died 2 months after the diagnosis of MDS.
  • Therapy-related MDS and AML (t-MDS/t-AML) developing after treatment for acute leukemia is unusual; the primary leukemia associated with most cases of t-MDS/t-AML is acute promyelocytic leukemia (APL).
  • This unusual case suggests that AML excluding APL should be considered a primary hematologic malignancy for t-MDS/t-AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chromosomes, Human, Pair 5. Cytarabine / analogs & derivatives. Leukemia, Myeloid, Acute / chemically induced. Monosomy. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / genetics


Advertisement
4. Tóthová E, Fricova M, Stecová N, Kafková A, Elbertová A: High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma; 2002;49(3):141-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
  • Flow cytometric expression of bcl-2 protein was analyzed in 67 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB subtype, CD34 expression and clinical outcome.
  • The number of bcl-2+ cells in each sample was heterogenous (range, 19% to 96%), with a mean of 81%.
  • The percentage of bcl-2+ cells was higher in M0 and M1 types according to French-American-British classification.
  • The mean fluorescence index (MFI), expressed as the ratio of sample channel:control mean channel was significantly higher (p=0.01) in M0 (19.0) and M1 (17.6) than M4 (11.7) and M5 (8.9) cytotypes.
  • High percentage expression of bcl-2 and MFI index of bcl-2 was associated with a low complete remission rate after intensive chemotherapy (40.4% in cases with 20% and more positive cells vs 72% in cases with less than 20% positive cells).
  • By statistical analysis we also demonstrated that both bcl-2 high MFI (>16) and CD34 expression are independent prognostic factors for achieving CR in AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / analysis. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12097997.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


5. Shafarenko M, Liebermann DA, Hoffman B: Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation. Blood; 2005 Aug 1;106(3):871-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation.
  • Thus, understanding functional interactions between genes that regulate normal blood cell development, including cell growth and differentiation, and how their altered expression contributes to leukemia, is important for rational drug design.
  • Ectopic expression of Egr-1 in M1 myeloblastic leukemia cells was observed to activate the macrophage differentiation program in the absence of the differentiation inducer interleukin 6 (IL-6) and to promote terminal differentiation in its presence.
  • In addition, we have shown that deregulated expression of the proto-oncogene c-myc blocks the myeloid terminal differentiation program.
  • Here we show that restoring expression of Egr-1 in M1 cells that express deregulated c-Myc abrogates the c-Myc block in terminal differentiation, resulting in cells that undergo functional macrophage maturation.
  • These findings indicate that Egr-1 can act as a tumor suppressor gene and suggest that Egr-1 or Egr-1 targets may provide important tools for differentiation therapy in certain leukemic phenotypes.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1993 May 1;81(9):2257-62 [8481508.001]
  • [Cites] Curr Opin Genet Dev. 1993 Feb;3(1):44-9 [8453273.001]
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5499-507 [7565701.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2439-44 [8570196.001]
  • [Cites] J Leukoc Biol. 1996 Aug;60(2):159-66 [8773576.001]
  • [Cites] Neurochem Int. 1997 Oct;31(4):477-510; discussion 517-6 [9307998.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11583-8 [9565575.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1957-66 [9731053.001]
  • [Cites] J Immunol. 1999 Jan 1;162(1):407-14 [9886414.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3351-7 [9916997.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):343-52 [9927191.001]
  • [Cites] J Biol Chem. 1999 Feb 12;274(7):4400-11 [9933644.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3004-16 [10378696.001]
  • [Cites] Cell. 1993 Jan 29;72(2):197-209 [7678779.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):2967-77 [10871848.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20315-23 [10783396.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1298-305 [11222373.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5595-610 [11607812.001]
  • [Cites] Oncogene. 2002 Feb 28;21(10):1600-10 [11896589.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3414-21 [12032779.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4259-67 [14982872.001]
  • [Cites] Cell. 1988 Apr 8;53(1):37-43 [3127059.001]
  • [Cites] Blood. 1990 Jan 1;75(1):82-7 [2403822.001]
  • [Cites] Cell. 1991 Jan 25;64(2):337-50 [1988151.001]
  • [Cites] Mol Cell Biol. 1991 May;11(5):2375-81 [1901940.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1915-22 [1923514.001]
  • [Cites] Science. 1992 Jul 10;257(5067):212-4 [1378649.001]
  • [Cites] Mol Cell Biol. 1993 Feb;13(2):841-51 [8423806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3260-5 [10737792.001]
  • [Cites] Ann N Y Acad Sci. 1994 May 31;716:327-30 [8024205.001]
  • (PMID = 15840692.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1 RO1 CA59774; United States / NCI NIH HHS / CA / 1 RO1 CA81168; United States / NCI NIH HHS / CA / CA88261-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Early Growth Response Protein 1; 0 / Egr1 protein, mouse; 0 / Immediate-Early Proteins; 0 / Myc protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC1895156
  •  go-up   go-down


6. Sperr WR, Hauswirth AW, Florian S, Ohler L, Geissler K, Valent P: Human leukaemic stem cells: a novel target of therapy. Eur J Clin Invest; 2004 Aug;34 Suppl 2:31-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human leukaemic stem cells: a novel target of therapy.
  • Acute myeloid leukaemia (AML) is a life-threatening haematopoietic disease that is characterized by clonal growth and the accumulation of myelopoietic progenitor cells.
  • Although AML cells only have a limited potential to undergo differentiation and maturation, each AML clone is organized in a hierarchical manner similar to normal haematopoiesis.
  • Recent data have shown that each AML clone consists of leukaemic stem cells and their progeny, and that AML stem cells differ from more mature cells in several aspects, including survival and target antigen profiles.
  • Most importantly, AML stem cells, but not their progeny, have the capacity to repopulate haematopoietic tissues with leukaemias in NOD/SCID mice.
  • Furthermore, AML stem cells are thought to be responsible for the infinite growth of leukaemias in patients with AML.
  • The phenotypic properties of AML stem cells have also been described.
  • In most cases, these cells are detectable within the CD34+, CD38-, Lin-, CD123+ subpopulation of AML cells.
  • Because of their AML-initiating and -renewing capacity and their unique phenotype, which includes several molecular targets of drug therapy, AML stem cells have recently been proposed as novel important target cell populations in the context of curative therapies.
  • The present article gives an overview of our knowledge about AML stem cells, their phenotype, and their role as a 'therapy-target' in new concepts to treat and to cure patients with AML.
  • [MeSH-major] Genetic Therapy / methods. Leukemia, Myeloid / therapy. Neoplastic Stem Cells

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15291804.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 108
  •  go-up   go-down


7. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti G, Del Vecchio L, Turco MC, Venuta S: Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides. Gene Ther; 2000 Jul;7(14):1234-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel- specific decoy oligodeoxynucleotides.
  • The activity of NF-kappa B/Rel nuclear factors is known to inhibit apoptosis in various cell types.
  • We investigated whether the subtraction of NF-kappa B/Rel activity influenced the response of 11 AML (M1, M2 and M4) patients' cells to AraC.
  • On the other hand, in 10 of the 11 samples tested, the decoy kappa B, but not the scrambled ODN significantly (P < 0.01 in a Student's t test) enhanced cell apoptotic response to AraC.
  • These findings indicate that NF-kappa B/Rel activity influences response to AraC in human primary myeloblastic cells, and suggests that the inhibition of NF-kappa B/Rel factors can improve the effect of chemotherapy in AML.
  • Gene Therapy (2000) 7, 1234-1237.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Leukemia, Myeloid, Acute / pathology. Oligodeoxyribonucleotides / genetics
  • [MeSH-minor] Apoptosis / drug effects. Genes, rel / physiology. Humans. NF-kappa B / physiology. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10918492.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / NF-kappa B; 0 / Oligodeoxyribonucleotides; 04079A1RDZ / Cytarabine
  •  go-up   go-down


8. Jelić-Puskarić B, Ostojić-Kolonić S, Planinc-Peraica A, Obad-Kovacević D, Kardum-Skelin I, Jaksić B: Myeloid sarcoma involving the breast. Coll Antropol; 2010 Jun;34(2):641-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma involving the breast.
  • Myeloid sarcoma is a tumor mass with extramedullary growth pattern, composed of myeloblasts or immature myeloid cells.
  • The development of myeloid sarcoma may precede or concur with acute or chronic myeloid leukemia (AML or CML) or other myeloproliferative diseases or myelodysplastic syndromes (MDS).
  • Isolated myeloid sarcoma of the breast is very rare.
  • Based on the morphology, cytochemical characteristics and immature cell immunophenotype, it was considered a case of acute myeloid leukemia without maturation.
  • In spite of intensive chemotherapy, the patient died within a year of diagnosis.
  • In cases of isolated breast myeloid sarcoma, the diagnosis can be missed if the possibility of myeloid sarcoma is not remembered on differential diagnosis of a breast neoplasm.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Anemia / etiology. Anemia / pathology. Biopsy, Fine-Needle. Bone Marrow / pathology. Fatal Outcome. Female. Humans. Leukemia, Myeloid, Acute / pathology. Leukocytosis / etiology. Leukocytosis / pathology. Recurrence. Thrombocytopenia / etiology. Thrombocytopenia / pathology

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698144.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


9. Ressel A, Trümper L, Bäsecke J: [Occlusion of the femoral arteries in de novo AML]. Med Klin (Munich); 2007 May 15;102(5):388-92
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occlusion of the femoral arteries in de novo AML].
  • [Transliterated title] Femoralarterienverschluss bei De-novo-AML.
  • BACKGROUND: Leukemic emboli in acute (AML) and chronic myelocytic leukemia (CML) are associated with hyperleukocytosis (>100,000/microl leukocytes) and most frequently detected at autopsy.
  • CASE REPORT: A 53-year-old woman was admitted with hyperleukocytosis and acute pain in her right leg.
  • An occlusion of the right femoral arteries as the presenting symptom of a de novo AML (FAB M1/WHO: AML without maturation) with hyperleukocytosis was diagnosed.
  • CONCLUSION: Leukemic emboli of large vessels are uncommon in leukemia with hyperleukocytosis.
  • Leukemic emboli mainly occur in AML and CML in blast crisis and are rare in acute (ALL) and chronic lymphocytic leukemia (CLL).
  • Therapeutic options, apart from the immediate start of chemotherapy, are leukapheresis and embolectomy.
  • [MeSH-major] Arterial Occlusive Diseases / etiology. Femoral Artery. Leukemia, Myeloid, Acute / diagnosis. Neoplastic Cells, Circulating
  • [MeSH-minor] Angiography. Blood Coagulation Tests. Diagnosis, Differential. Female. Granulocyte Precursor Cells / pathology. Humans. Leukocyte Count. Leukocytosis / diagnosis. Leukocytosis / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497090.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Li S, Zhang L, Kern WF, Andrade D, Forsberg JE, Bates FR, Mulvihill JJ: Identification of t(15;17) and a segmental duplication of chromosome 11q23 in a patient with acute myeloblastic leukemia M2. Cancer Genet Cytogenet; 2002 Oct 15;138(2):149-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of t(15;17) and a segmental duplication of chromosome 11q23 in a patient with acute myeloblastic leukemia M2.
  • A 32-year-old man was newly diagnosed with acute myelocytic leukemia, classified as acute myeloblastic leukemia with maturation (AML-M2) according to the French-American-British classification system.
  • Conventional chromosome analysis before chemotherapy treatment revealed an abnormal karyotype: a possible segmental duplication of 11q23, plus a translocation between chromosomes 15 and 17 [t(15;17) (q22;q21.1)] in the majority of cells analyzed.
  • To our knowledge, this is the first report of a combination of t(15;17) and a segmental duplication of 11q23 in a patient with AML-M2.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Gene Duplication. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Chromosome 17, Duplication.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12505261.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Yan ZQ, Bolognesi MP, Steeber DA, Tedder TF, Chen LE, Seaber AV, Urbaniak JR: Blockade of L-selectin attenuates reperfusion injury in a rat model. J Reconstr Microsurg; 2000 Apr;16(3):227-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using a rat extensor digitorum longus (EDL) muscle model, the present study tested the hypothesis that in vivo administration of the function-blocking monoclonal antibody (mAb) LAM1-116 which recognizes L-selectin, a cell-surface adhesion receptor, could decrease I/R injury.
  • In 46 rats, one EDL served as a normal control and the opposite EDL underwent 3 hr of ischemia followed by 3 hr of reperfusion after pretreatment with LAM1-116 mAb, control IgG, or saline.
  • Myeloperoxidase (MPO) activity showed only a two-fold increase from normal in LAM1-116-treated I/R EDL while a 27-fold increase occurred in the IgG2a and saline groups, with a statistically significant (p < 0.001) difference.
  • A significantly (p < 0.05) lower wet weight ratio, improved fatigue contractile force, and less neutrophil infiltration were found in LAM1-116-treated EDL, when compared to those in control IgG- or saline-treated EDL.
  • The results indicate that blockade of L-selectin by LAM1-116 mAb can effectively reduce neutrophil infiltration in reperfused skeletal muscle, thereby decreasing tissue edema and improving muscle fatigue contractile force.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. L-Selectin / drug effects. Peroxidase / metabolism. Reperfusion Injury / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Dose-Response Relationship, Drug. Female. Immunoglobulin G / metabolism. Immunoglobulin G / pharmacology. Leukocyte Count / drug effects. Muscle Contraction / drug effects. Muscle, Skeletal / pathology. Organ Size / drug effects. Rats. Rats, Sprague-Dawley. Reference Values. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10803628.001).
  • [ISSN] 0743-684X
  • [Journal-full-title] Journal of reconstructive microsurgery
  • [ISO-abbreviation] J Reconstr Microsurg
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-26872; United States / NHLBI NIH HHS / HL / HL 36046; United States / NHLBI NIH HHS / HL / HL-50985; etc
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 126880-86-2 / L-Selectin; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


12. Guo C, Inghirami G, Ibrahim S, Sen F: Epistaxis and severe weakness in a patient with multiple myeloma. Therapy-related acute myeloid leukemia, pure erythroid leukemia. Arch Pathol Lab Med; 2006 Jul;130(7):1075-6
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epistaxis and severe weakness in a patient with multiple myeloma. Therapy-related acute myeloid leukemia, pure erythroid leukemia.
  • Therapy-related acute myeloid leukemias arise as a result of cytotoxic chemotherapy and/or radiation therapy.
  • The most common types of acute myeloid leukemia arising in this setting are acute myeloid leukemia with maturation, and lesser numbers of acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, or acute megakaryocytic leukemia.
  • We present a patient with multiple myeloma who was treated with melphalan and 4 years later developed acute erythroid leukemia.
  • The morphologic diagnosis of pure erythroid leukemia developing in the setting of multiple myeloma may be challenging.
  • [MeSH-major] Epistaxis / complications. Leukemia, Erythroblastic, Acute / complications. Multiple Myeloma / complications. Muscle Weakness / complications
  • [MeSH-minor] Acute Disease. Aged, 80 and over. Antineoplastic Agents, Alkylating / adverse effects. Humans. Leukemia, Myeloid. Male. Melphalan / adverse effects

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831041.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


13. Wong KF, Yuen HL, Siu LL, Pang A, Kwong YL: t(8;16)(p11;p13) predisposes to a transient but potentially recurring neonatal leukemia. Hum Pathol; 2008 Nov;39(11):1702-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(8;16)(p11;p13) predisposes to a transient but potentially recurring neonatal leukemia.
  • A Chinese girl presented with generalized papular rash and monocytic leukemia 19 days after birth.
  • Cytogenetic analysis showed t(8;16)(p11.2;p13.3) as the sole chromosomal abnormality.
  • Spontaneous regression of the leukemia was observed after 2 months, although the t(8;16) translocation persisted cytogenetically.
  • This was followed 7 months later by the development of acute myeloid leukemia with maturation and cytogenetic evolution with extra chromosomes 4 and 8.
  • Molecular study showed that the reciprocal MYST3 and CREBBP gene fusion characteristic of t(8;16) translocation persisted throughout the clinical course, even during spontaneous regression of the neonatal leukemia, and after chemotherapy-induced remission of the subsequent acute myeloid leukemia.
  • The possible role of MYST3 and CREBBP gene fusion in the pathogenesis of the leukemia is discussed.
  • [MeSH-major] Leukemia, Monocytic, Acute / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657848.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CREBBP protein, human; EC 2.3.1.48 / CREB-Binding Protein; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


14. Watanabe A, Koike K, Fukushima T, Izumi I, Ohba K, Tsuchida M: [Complex translocation (8;15;21) (q22;p12;q22) in a child with AML-M2 showing de novo appearance of the short form of AML1-MTG8 chimeric mRNA during the course]. Rinsho Ketsueki; 2001 Feb;42(2):110-4
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complex translocation (8;15;21) (q22;p12;q22) in a child with AML-M2 showing de novo appearance of the short form of AML1-MTG8 chimeric mRNA during the course].
  • A 4-year-old boy admitted with exophthalmos was diagnosed as having acute myeloblastic leukemia with maturation (AML-M2).
  • During chemotherapy, RT-PCR demonstrated the short form of AML1-MTG8 mRNA, in addition to chimeric mRNA of the usual length.
  • A literature search failed to reveal any similar cases of t(8;21) AML-M2 associated with this deletion of chimeric mRNA.
  • [MeSH-major] Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Myeloid, Acute / genetics. RNA, Messenger / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11280916.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


15. McGrattan P, Alexander HD, Humphreys MW, Kettle PJ: Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation. Cancer Genet Cytogenet; 2002 Jun;135(2):192-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetrasomy 13 as the sole cytogenetic abnormality in acute myeloid leukemia M1 without maturation.
  • We report a case of acute myeloid leukemia (AML) M1 showing a 48,XY,+13,+13 karyotype.
  • Treatment was according to the Medical Research Council AML14 trial protocol with two courses of DAT chemotherapy.
  • Tetrasomy 13 as the sole cytogenetic abnormality has not been reported previously in M1 AML and has only been reported in three other AML cases, all with an immature phenotype and poor outcome.
  • [MeSH-major] Aneuploidy. Chromosomes, Human, Pair 13. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Drug Resistance, Neoplasm. Fatal Outcome. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Thioguanine / administration & dosage. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12127406.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; FTK8U1GZNX / Thioguanine; ZS7284E0ZP / Daunorubicin; DAT protocol 1; FLAG protocol
  • [Number-of-references] 10
  •  go-up   go-down


16. Matsuo K, Shimoya K, Ueda S, Wada K, Koyama M, Murata Y: Idarubicin administered during pregnancy: its effects on the fetus. Gynecol Obstet Invest; 2004;58(4):186-8
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute myeloblastic leukemia, subtype M1, was diagnosed in a 39-year-old G2P1 Japanese woman at 21 weeks' gestation.
  • Second-line chemotherapy, including idarubicin, performed for one cycle, was administrated during the early third trimester of pregnancy.
  • Complete remission was established with idarubicin including chemotherapy.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fetus / drug effects. Idarubicin / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Cesarean Section. Drug Therapy, Combination. Female. Gestational Age. Heart Rate, Fetal / drug effects. Humans. Placenta / drug effects. Placenta / pathology. Pregnancy. Shock, Septic / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15256824.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; ZRP63D75JW / Idarubicin
  •  go-up   go-down


17. Inuzuka M, Tokura Y: Sterile suppurative folliculitis associated with acute myeloblastic leukaemia. Br J Dermatol; 2002 May;146(5):904-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sterile suppurative folliculitis associated with acute myeloblastic leukaemia.
  • A 20-year-old woman presented with a 4-month history of follicular papules distributed over the trunk and extremities.
  • One month later, routine blood tests were abnormal, showing acute myeloblastic leukaemia (M1 in the French-American-British classification).
  • The follicular eruption improved promptly in response to chemotherapy for the leukaemia.
  • We suggest that this case may represent a rare, follicular variant of neutrophilic dermatosis associated with myelogenous leukaemia.
  • [MeSH-major] Folliculitis / etiology. Leukemia, Myeloid, Acute / complications. Sweet Syndrome / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000394.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Hiçsönmez G: The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis. Leuk Res; 2006 Jan;30(1):60-8
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of steroid on myeloid leukemic cells: the potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis.
  • Several in vitro studies have shown that dexamethasone (Dex) and prednisolone can induce differentiation of some mouse and human myeloid leukemic cells to macrophages and granulocytes.
  • Based on in vitro experiments, we have shown that short-course (3-7 days) high-dose methylprednisolone (HDMP) (20-30 mg/kg/day) treatment can induce differentiation of myeloid leukemic cells in vivo in children with different subtypes of acute myeloblastic leukemia (AML) (AML-M1, -M2, -M3, -M4, -M7).
  • We have also shown that induction of apoptosis of myeloid leukemic cells with or without differentiation is possible by short-course HDMP treatment.
  • In addition, short-course HDMP treatment has been shown to be effective in accelerating leukocyte recovery, possibly stimulating normal CD34-positive hematopoietic progenitor cells.
  • Addition of HDMP to mild cytotoxic chemotherapy (low-dose cytosine arabinoside (LD-Ara-c), weekly mitoxantrone and Ara-c or 6-thioguanine) increased the remission rate (87-89%) and improved the outcome of AML children.
  • We believe that the results of our 17-year clinical experience will provide important benefits to AML patients.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Apoptosis / drug effects. Cell Differentiation / drug effects. Leukemia, Myeloid, Acute / metabolism. Methylprednisolone / pharmacology. Myelopoiesis / drug effects
  • [MeSH-minor] Animals. Antigens, CD34 / metabolism. Child. Child, Preschool. Female. Hematopoietic Stem Cells / metabolism. Hematopoietic Stem Cells / pathology. Humans. Leukocytes / metabolism. Leukocytes / pathology. Male. Mice. Recovery of Function / drug effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979702.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antigens, CD34; X4W7ZR7023 / Methylprednisolone
  • [Number-of-references] 111
  •  go-up   go-down


19. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H: Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol; 2004 Feb;72(2):89-106
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
  • There is evidence to suggest, that those receptors (R) could play a role in leukemia with respect to cell differentiations and its regulation, prognosis, and pathobiology.
  • Knowledge of individual cytokine receptor (CKR) profiles could provide new discoveries about CKR-supported therapeutic considerations.
  • METHODS: We have studied the expression of CKR on mononuclear bone marrow (BM) cells of 89 patients with acute myeloid leukemia (AML) at first diagnosis, three patients at relapse or with persisting AML and eight healthy probands by fluorescence-activated cell sorting (FACS) analysis using directly fluorescein-conjugated antibodies: CD114 (hG-CSF-R), CD116 (hGM-CSF-R), CD117 (hSCF-R), CD123 (hIL-3-R), CD130 (gp130subunit), CD135 (hFL-R).
  • RESULTS: All investigated CKR were more frequently expressed in AML-samples than in healthy BM-samples, except CD130, which was only expressed on 5-6% of AML-blasts in all and with only one healthy BM-sample being CD130(+).
  • Within the French-American-British (FAB) types we observed a maturation- and lineage (granulocytic/monocytic)-committed expression profile.
  • Monocytic subtypes (FAB-type M4/M5) showed significantly more GM-CSF-R(+) (P = 0.001) and FL-R(+) (P = 0.001) and significantly less stem cell factor-R (SCF-R(+)) (P = 0.02) cases.
  • Highest proportions of G-CSF-R(+) blasts were observed in FAB-type M3.
  • In undifferentiated leukemias (FAB-type M1, M2) high amounts of SCF-R(+), IL-3-R(+), and FL-R(+) blasts could be detected.
  • FL-R was the only CKR, which was positive in FAB-type M0 (n = 2).
  • For clinical evaluation only patients treated by the AML-CG-protocol, were included (n = 53).
  • CONCLUSION: We can conclude, that CKR-expression in AML is maturation- and lineage-committed and the proportions of especially early acting CKR have influence on relapse-free survival probability of AML-patients, independently of the karyotype.
  • With respect to the individual CKR status the benefit of cytokines as priming agents, as agents to treat neutropenia or to influence the metabolism of chemotherapy can be discussed under new points of view.
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Receptors, Cytokine / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Recurrence. Time Factors


20. Nakai K, Tajima K, Kishimoto Y, Katsura K, Kawamura M, Yamamoto Y, Hanada M, Zen K, Amakawa R, Fujimoto M, Fukuhara S: [Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance]. Rinsho Ketsueki; 2000 Jan;41(1):25-31
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In October 1996, a 26-year-old woman was given a diagnosis of acute myeloblastic leukemia, FAB subtype M1.
  • Treatment with combined chemotherapy achieved a complete remission (CR).
  • Successful engraftment was obtained and signs of acute or chronic GVHD never developed.
  • The patient also exhibited hemolytic anemia with red cell fragmentation, thrombocytopenia, elevated lactate dehydrogenase, and renal impairment, and was thus given a diagnosis of BMT-associated thrombotic microangiopathy (BMT-TM).
  • Single-photon-emission computed tomography revealed blood-flow disturbances in the brain, suggesting the recurrence of microthrombosis.
  • Currently, early diagnosis of BMT-TM is considered to be difficult.
  • We suggest that careful examination of the ocular base may be useful for the early detection of BMT-TM.
  • [MeSH-minor] Adult. Aspirin / therapeutic use. Dipyridamole / therapeutic use. Female. Humans. Leukemia, Myeloid, Acute / therapy. Microcirculation. Plasma. Prednisolone / therapeutic use. Recurrence. Treatment Outcome


21. Øyan AM, Bø TH, Jonassen I, Gjertsen BT, Bruserud Ø, Kalland KH: cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. Int J Oncol; 2006 May;28(5):1065-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • Acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology and clinical course.
  • Until now the basis for prognostic evaluation and therapeutic decision has been the karyotype, genetic FLT3 abnormalities and the initial chemotherapy response.
  • In an attempt to address this question, we performed cDNA microarray analysis on peripheral blood samples of 25 patients with newly diagnosed AML with high blast counts.
  • Leave-one-out crossvalidation (LOOCV) showed with high accuracy that gene expression classifiers could predict if leukaemia samples belonged to the FAB AML-M1 or to the FAB AML-M2 groups.
  • Except for an accumulation of samples classified as FAB M1 and M2 in cluster 3, there was no evident relationship between the clusters and the FAB classification.
  • Each subgroup displayed clearly distinguished gene expression patterns validated using real-time quantitative PCR analysis.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Oligonucleotide Array Sequence Analysis


22. Okamoto Y, Tsuda T, Matsunami M, Hirose T, Sakaguchi R, Katayama N, Ota K: Treatment of acute myeloblastic leukaemia in a patient with Bombay blood type: a case report. J Int Med Res; 2001 Mar-Apr;29(2):140-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute myeloblastic leukaemia in a patient with Bombay blood type: a case report.
  • A 62-year-old female was admitted to our hospital with suspected acute leukaemia and after investigation we diagnosed acute myeloblastic leukaemia (AML-M1).
  • The patient's blood type was found to be the very rare Bombay type and surveillance of her relatives showed the same blood type in her male cousin on her mother's side.
  • Alongside chemotherapy the patient received 4000 ml of frozen Bombay-type red cells, 1400 ml of concentrated red cells in manitol adenine phosphate solutions and 360 units of type O concentrated platelets without marked effects.
  • The anti-H antibody was initially at 128 dilution but for unknown reasons increased to 2048 dilution after remission of AML-M1.
  • Although AML-M1 is a common adult leukaemia and is chemosensitive to anti-leukaemic drugs, neither AML-M1 in a patient with Bombay-type red cells nor its treatment with chemotherapy and transfusion with type Oh frozen red cells have previously been reported.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Blood Group Antigens. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11393347.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Blood Group Antigens
  •  go-up   go-down


23. Tóthová E, Stecová N, Kafková A, Fricová M, Guman T, Elbertová A: [Relation between Bcl-2 protein expression and results of therapy in patients with acute myeloblastic leukemia]. Vnitr Lek; 2004 Feb;50(2):139-42
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between Bcl-2 protein expression and results of therapy in patients with acute myeloblastic leukemia].
  • Flow cytometric expression of Bcl-2 protein was analyzed in 67 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-Bcl-2 monoclonal antibody by direct immunofluorescence technique and result were correlated with FAB subtype, CD34 expression and clinical outcome.
  • The percentage of Bcl-2+ cells was higher in M0 and M1 types according French-American-British classification.
  • The mean fluorescence index (MFI), expressed as the ratio of sample channel: control mean channel was significantly higher (p < 0.01) in M0 (19.0) and M1 (17.6) than M4 (11.7) and M5 (8.9) cytotypes.
  • High percentage expression of Bcl-2 and MFI index of Bcl 2 was associated with a low complete remission rate after intensive chemotherapy (40.4% in cases with 20% and more positive cells vs 72% in cases with less than 20% positive cells).
  • By statistical analysis we also demonstrated that both Bcl-2 high MFI (> 16) and CD34 expression are independent prognostic factors for achieving CR in AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / analysis. Female. Fluorescent Antibody Technique, Direct. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15077589.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


24. Lesesve JF, Dugué F, Grégoire MJ, Witz F, Dror Y: Shwachman-Diamond syndrome with late-onset neutropenia and fatal acute myeloid leukaemia without maturation: a case report. Eur J Haematol; 2003 Nov;71(5):393-5
Genetic Alliance. consumer health - Shwachman syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shwachman-Diamond syndrome with late-onset neutropenia and fatal acute myeloid leukaemia without maturation: a case report.
  • We report on a male patient affected by Shwachman Diamond syndrome (SDS) who presented an unusual delayed neutropenia and then developed a poorly differentiated acute myeloid leukaemia (M0-AML) with trilineage myelodysplasia in adulthood.
  • The patient was treated with conventional chemotherapy but never reached complete remission of leukaemia and died 18 months after diagnosis.
  • SDS is an inherited bone marrow failure syndrome with a high propensity to leukaemic transformation.
  • [MeSH-major] Exocrine Pancreatic Insufficiency / complications. Leukemia, Myeloid / etiology. Neutropenia / etiology
  • [MeSH-minor] Acute Disease. Cell Differentiation. Child. Fatal Outcome. Genetic Predisposition to Disease. Humans. Male. Pancytopenia / etiology. Sepsis / etiology. Syndrome

  • Genetic Alliance. consumer health - Shwachman-Diamond syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14667205.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


25. Laatiri MA, Chehata S, Amouri A, Bouaouina N, Chatti S, Saad A, Ennabli S: [Childhood acute myeloblastic leukemias. Report of 21 cases]. Tunis Med; 2000 Mar;78(3):167-71
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood acute myeloblastic leukemias. Report of 21 cases].
  • [Transliterated title] Leucémies aiguës myéloblastiques de l'enfant. A propos de 21 cas.
  • Between 1989 and 1996, 21 cases with acute non lymphoblastic leukemia (11 males and 10 females) were diagnosed in our institution.
  • According to the French-American-British (FAB) criteria, 7 cases were classified M1, 10 cases were classified M2, 1 classified M4Eo and 3 classified M5.
  • The 3-year survival rate was 20% and the relapse-free-survival rate was 12% confirming the worse prognosis of this leukemia when treated with standard chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Monocytic, Acute / diagnosis. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / diagnosis. Leukemia, Myelomonocytic, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11026819.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] TUNISIA
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


26. Reisch N, Roehnisch T, Sadeghi M, Greiner L, Regenbogen C, Rieger J, Emmerich B, Oduncu F: AML M1 presenting with recurrent acute large arterial vessel thromboembolism. Leuk Res; 2007 Jun;31(6):869-71
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AML M1 presenting with recurrent acute large arterial vessel thromboembolism.
  • Acute leukemia may be associated with coagulopathy, predominantly severe bleeding diathesis caused by disseminated intravascular coagulation (DIC) and/or hyperfibrinolysis.
  • Disordered hemostasis is characteristic for acute promyelocytic leukemia (APL, FAB M3).
  • We report a case of severe recurrent acute arterial thromboembolism at presentation in AML FAB M1.
  • Most likely, the ischemic events in our patient resulted from leukemia as the thrombus material included many leukemic blasts.
  • Despite leg amputation just a couple of hours before and extremely high infectious risk of the patient, chemotherapy was administered.
  • The clinical course of cessation of the ischemic events and a fast reduction of the blasts in the peripheral blood smear after chemotherapeutic treatment of the patient outlines the importance and life saving role of early chemotherapy even under adverse circumstances.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Thromboembolism / etiology
  • [MeSH-minor] Adult. Amputation. Disseminated Intravascular Coagulation / etiology. Female. Hemorrhagic Disorders / etiology. Humans. Iliac Artery / pathology. Iliac Artery / radiography. Ischemia / etiology. Ischemia / pathology. Ischemia / radiography. Ischemia / surgery. Leg / blood supply. Leg / pathology. Leg / radiography. Leg / surgery. Leukemia, Promyelocytic, Acute / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011031.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood; 2007 Jan 15;109(2):740-6
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
  • Arsenic trioxide (As2O3) is highly efficacious in acute promyelocytic leukemia (APL).
  • In 10 of 11 myeloid and lymphoid leukemia lines, quantitative polymerase chain reaction (Q-PCR) and Western blotting showed that AQP9 expression correlated positively with As2O3-induced cytotoxicity.
  • Similarly, the chronic myeloid leukemia line K562 expressed low levels of AQP9 and was As2O3 insensitive.
  • Pretreatment of the myeloid leukemia line HL-60 with all-trans retinoic acid (ATRA) up-regulated AQP9, leading to a significantly increased arsenic uptake and As2O3-induced cytotoxicity on incubation with As2O3, which might explain the synergism between ATRA and As2O3.
  • Q-PCR showed that primary APL cells expressed AQP9 significantly (2-3 logs) higher than other acute myeloid leukemias (AMLs), which might explain their exquisite As2O3 sensitivity.
  • However, APL and AML with maturation expressed comparable AQP9 levels, suggesting that AQP9 expression was related to granulocytic maturation.
  • [MeSH-major] Aquaporins / metabolism. Arsenicals / pharmacology. Leukemia, Myeloid / metabolism. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Oxides / pharmacology
  • [MeSH-minor] Acute Disease. Cell Line, Tumor. Cell Proliferation / drug effects. Gene Expression Profiling. Humans. K562 Cells. Point Mutation. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity. Tretinoin / pharmacology. Up-Regulation / drug effects

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968895.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP9 protein, human; 0 / Aquaporins; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


28. Herry A, Douet-Guilbert N, Guéganic N, Morel F, Le Bris MJ, Berthou C, De Braekeleer M: Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association. Ann Hematol; 2006 Apr;85(4):244-9
Hazardous Substances Data Bank. PIPOBROMAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association.
  • We report here a 71 year-old female presenting with acute myeloblastic leukemia (FAB-M1) after treatment of essential thrombocythemia with Vercyte.
  • Twenty-one cases, including ours, of myelodysplastic syndromes and acute myelogenous leukemia with MLL amplification present in hsr or dmin were found in the literature.
  • Most of these patients shared some characteristics: they were old, they had de novo acute myeloid leukemia (AML) with a complex karyotype and a short survival, 90% of them having also a del(5q).
  • Therefore, the simultaneous presence of MLL amplification and del(5q) appears to be a nonrandom association that could be the signature of AML in elderly patients with a poor prognosis.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 7 / genetics. Gene Amplification. Leukemia, Myeloid, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Aged. Cytogenetic Analysis. Fatal Outcome. Female. Histone-Lysine N-Methyltransferase. Humans. In Situ Hybridization, Fluorescence / methods. Karyotyping. Pipobroman / therapeutic use. Prognosis. Sensitivity and Specificity. Thrombocytosis / diagnosis. Thrombocytosis / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425025.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6Q99RDT97R / Pipobroman; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


29. Monteleone PM, Steele DA, King AK, Konefal S, Kelleher JF: Bilateral breast relapse in acute myelogenous leukemia. J Pediatr Hematol Oncol; 2001 Feb;23(2):126-9
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral breast relapse in acute myelogenous leukemia.
  • We present the case of an 11.5-year-old girl with M1 acute myelogenous leukemia (AML) who had isolated extramedullary relapse develop in both breasts 12 months after diagnosis and 7 months off chemotherapy.
  • She received further chemotherapy, focal radiation therapy, then underwent a matched, unrelated bone marrow transplant and continues in remission 37 months later.
  • Review of the literature revealed 10 cases in other children younger than 21-years-old with AML and breast involvement.
  • Breast involvement in AML is rare in children.
  • However, regular breast examinations should be performed as part of routine follow-up in all girls with AML.
  • [MeSH-major] Breast / pathology. Leukemia, Myeloid, Acute / pathology. Vidarabine / analogs & derivatives
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Marrow Transplantation. Child. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Graft vs Host Disease / etiology. Humans. Idarubicin / administration & dosage. Immunologic Factors / therapeutic use. Interleukin-2 / therapeutic use. Leukemic Infiltration. Radiotherapy, High-Energy. Recurrence. Salvage Therapy. Thioguanine / administration & dosage. Transplantation Conditioning

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11216705.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interleukin-2; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; FA2DM6879K / Vidarabine; FTK8U1GZNX / Thioguanine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 23
  •  go-up   go-down


30. Baines P, Fisher J, Truran L, Davies E, Hallett M, Hoy T, Burnett AK: The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. Eur J Haematol; 2000 Apr;64(4):211-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro.
  • The appearance of blasts in acute myeloid leukemia (AML) reflects a shift from cellular processes inducing maturation and cell death to those favouring survival and accumulation.
  • We have monitored changes in the growth factor signalling molecule MAPKinase, in the cytoprotective protein Bcl-2 and in the cell death protein Bax, during maturation of proliferating and non-proliferating AML blasts in vitro.
  • Eighteen AML samples were cultured for 7 d in serum-free medium with or without a supplement of recombinant cytokines comprising c-kit ligand, IL3 and GMCSF.
  • Maturation of AML blasts, as assessed by morphology on Romanowsky-stained slides of 7/18 samples and by changes in surface CD markers on all 18 leukemias, occurred in both the absence and presence of cytokines.
  • Immunoblotting demonstrated that ERK was briefly phosphorylated after seeding AML blasts into culture.
  • PD98059, an inhibitor of MAPKinase kinase (MEK) which activates MAPKinase, inhibited this transient ERK phosphorylation but was unable to block maturation as measured by acquisition of CD15 in samples from 12 patients with low starting numbers of CD15-positive cells.
  • PD98059, however, reduced cell numbers in 7-d liquid culture and, in cytokine-supplemented cultures, this was associated with a 1.3-fold increase in Bcl-2 (p = 0.012) and a 1.4-fold increase in Bax (p = 0.02).
  • The MAPKinase pathway is not required for this maturation, but it does maintain cell viability in the absence or presence of cytokines.
  • A rise in Bcl-2 may not protect AML blasts in the face of elevated Bax.
  • [MeSH-major] Enzyme Inhibitors / pharmacology. Flavonoids / pharmacology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adult. Aged. Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors. Cell Differentiation / drug effects. Cell Survival / drug effects. Female. Humans. Male. Middle Aged. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Signal Transduction / drug effects. Tumor Cells, Cultured. bcl-2-Associated X Protein

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10776691.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / BAX protein, human; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


31. Taguchi A, Tominaga T, Nakamori Y, Miyazaki M, Shinohara K: Two cases of acute myeloblastic leukemia evolving from aplastic anemia. Int J Hematol; 2003 Jun;77(5):471-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of acute myeloblastic leukemia evolving from aplastic anemia.
  • Two cases of acute myeloblastic leukemia (AML) evolving from aplastic anemia are presented.
  • The first case was diagnosed 18 years ago, and treatment with bolus methylprednisolone, prednisolone, and androgens resulted in partial hematological response.
  • Severe pancytopenia recurred, and AML M0 by French-American-British classification developed.
  • The patient had HLA DRB1*1501, and treatment with granulocyte colony-stimulating factor (G-CSF), cyclosporine, and methenolone resulted in complete hematological response.
  • Thrombocytopenia recurred and did not respond to cyclosporine and methenolone or to later treatment with antithymocyte globulin, and AML M1 developed.
  • These patients were treated with cytosine arabinoside, aclacinomycin, and G-CSF (CAG) chemotherapy, and the number of leukemic cells decreased substantially.
  • However, pancytopenia after CAG chemotherapy persisted, and the first patient died of pneumonia and the second patient of cerebral hemorrhage.
  • [MeSH-major] Anemia, Aplastic / pathology. Leukemia, Myeloid, Acute / etiology
  • [MeSH-minor] Child. Cytogenetic Analysis. DNA Mutational Analysis. Fatal Outcome. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. HLA-DR Antigens / analysis. Hormones / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Pancytopenia / etiology

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 May 1;99(9):3129-35 [11964274.001]
  • [Cites] Exp Hematol. 1987 Dec;15(11):1134-9 [3315724.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3897-902 [12393738.001]
  • [Cites] Br J Haematol. 1988 Sep;70(1):55-62 [3179229.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1385-92 [1547338.001]
  • [Cites] Blood. 1996 Sep 15;88(6):1930-5 [8822909.001]
  • [Cites] Am J Med. 1981 Oct;71(4):543-51 [7282742.001]
  • [Cites] Nature. 1987 Jun 4-10;327(6121):430-2 [3295562.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1931-4 [10706857.001]
  • [Cites] Br Med J. 1971 Jun 26;2(5764):743-5 [5282950.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):271-4 [10050707.001]
  • [Cites] Blood. 1992 May 15;79(10):2566-71 [1586708.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1009-13 [9242530.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1031-7 [12130519.001]
  • [Cites] Leukemia. 1995 Jan;9(1):10-4 [7531259.001]
  • [Cites] Ann Intern Med. 2002 Apr 2;136(7):534-46 [11926789.001]
  • [Cites] Blood. 2002 Aug 1;100(3):786-90 [12130487.001]
  • [Cites] Leukemia. 2002 Dec;16(12):2366-78 [12454741.001]
  • [Cites] Semin Hematol. 2000 Jan;37(1):91-101 [10676914.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2222-8 [2257296.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3513-9 [11739151.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Br J Haematol. 1988 Jul;69(3):413-8 [3044440.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):505-11 [10583249.001]
  • [Cites] Br J Haematol. 1991 Apr;77(4):447-52 [2025570.001]
  • [Cites] Br J Haematol. 1989 Sep;73(1):121-6 [2803967.001]
  • [Cites] J Clin Pathol. 1988 Jul;41(7):763-7 [3410972.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4257-61 [7994040.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3542-52 [7579462.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1152-7 [8377778.001]
  • [Cites] Blood. 1987 Oct;70(4):1046-52 [3651599.001]
  • [Cites] N Engl J Med. 1992 May 7;326(19):1294-5 [1373226.001]
  • (PMID = 12841385.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / Hormones; 0 / Immunosuppressive Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


32. Charrad RS, Gadhoum Z, Qi J, Glachant A, Allouche M, Jasmin C, Chomienne C, Smadja-Joffe F: Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood; 2002 Jan 1;99(1):290-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines.
  • Acute myeloid leukemia (AML) is a heterogeneous leukemia characterized by the blockage of myeloid differentiation at different stages, which define distinct AML subtypes.
  • We have recently reported that the ligation of CD44 with 2 activating monoclonal antibodies (mAbs), A3D8 and H90, triggers terminal differentiation of leukemic blasts in AML-M1/2 to AML-M5 subtypes, which are the most frequent ones.
  • However, fresh AML blasts have short in vitro lifespans.
  • Therefore, to find relevant in vitro cellular models for further studying the mechanisms involved in CD44-induced differentiation, we investigated whether CD44 ligation with A3D8 and H90 mAbs can induce terminal differentiation of THP-1, NB4, and HL60 cells, each interesting models of AML-M5 (monoblastic subtype), AML-M3 (promyelocytic subtype), and AML-M2 (myeloblastic subtype), respectively.
  • We also study whether CD44 ligation induces a loss of proliferative capacity, an important feature of late-stage myeloid differentiation.
  • In the second part of our study, we investigated whether A3D8 and H90 anti-CD44 mAbs can induce the differentiation and inhibit the proliferation of KG1a cells, which are very immature AML-M0 blasts.
  • Finally, our results demonstrate for the first time that it is possible to reverse the leukemic blockage of KG1a cells by using both an anti-CD44 mAb and retinoic acid.
  • This result may provide a new experimental basis for a differentiative therapy in AML-M0 patients.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD44 / physiology. Apoptosis. Cell Differentiation. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Cell Division / drug effects. Granulocytes / pathology. HL-60 Cells / pathology. Humans. Tretinoin / pharmacology. Tumor Cells, Cultured


33. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ: The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer; 2005 Dec 12;93(12):1388-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
  • Cytarabine (ara-C) is the most effective agent for the treatment of acute myeloid leukaemia (AML).
  • Aberrant expression of enzymes involved in the transport/metabolism of ara-C could explain drug resistance.
  • We determined mRNA expression of these factors using quantitative-real-time-PCR in leukemic blasts from children diagnosed with de novo AML.
  • Expression of the inactivating enzyme pyrimidine nucleotidase-I (PN-I) was 1.8-fold lower in FAB-M5 as compared to FAB-M1/2 (P=0.007).
  • In conclusion, decreased expression of hENT1, which transports ara-C across the cell membrane, appears to be a major factor in ara-C resistance in childhood AML.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Cytarabine / pharmacology. Equilibrative Nucleoside Transporter 1 / physiology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Cell Membrane. Child. Drug Resistance, Neoplasm. Gene Expression Profiling. Humans. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1999 Mar;104(3):630-9 [10086807.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] Br J Haematol. 1999 Jul;106(1):78-85 [10444166.001]
  • [Cites] Klin Padiatr. 1999 Jul-Aug;211(4):239-44 [10472557.001]
  • [Cites] Leukemia. 2005 Apr;19(4):537-44 [15690069.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):55-61 [11333300.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2914-27 [11032837.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7217-24 [11585758.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):691-7 [12628850.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1075-6 [12921942.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7524-36 [14576856.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Dec;4(12):1442-50 [14763130.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S108-12 [15124698.001]
  • [Cites] Cancer Res. 1978 Mar;38(3):579-85 [203385.001]
  • [Cites] J Clin Invest. 1982 Feb;69(2):479-89 [6948829.001]
  • [Cites] Mol Pharmacol. 1983 Jan;23(1):159-64 [6306421.001]
  • [Cites] Science. 1983 Aug 5;221(4610):514-9 [6306767.001]
  • [Cites] Semin Oncol. 1985 Jun;12(2 Suppl 3):65-74 [3892704.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5952-7 [4053067.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1079-83 [3484676.001]
  • [Cites] Pharmacol Ther. 1985;30(3):287-99 [2433703.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):159-66 [3589690.001]
  • [Cites] Leukemia. 1988 May;2(5):253-60 [3287015.001]
  • [Cites] Blood. 1990 Dec 1;76(11):2327-36 [2257305.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2559-65 [2021937.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):469-74 [1911186.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2389-93 [1568208.001]
  • [Cites] Leukemia. 1993 Jul;7(7):1005-11 [7686601.001]
  • [Cites] Cancer Surv. 1993;17:123-56 [8137339.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1224-9 [8035616.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5401-7 [7923172.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1047-52 [7981053.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3097-108 [7579404.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1864-9 [7475276.001]
  • [Cites] Leuk Res. 1996 Aug;20(8):677-82 [8913321.001]
  • [Cites] Adv Cancer Res. 1998;72:197-233 [9338077.001]
  • [Cites] FEBS Lett. 1997 Dec 15;419(2-3):263-7 [9428647.001]
  • [Cites] Adv Exp Med Biol. 1998;431:667-71 [9598149.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]
  • [Cites] Trends Pharmacol Sci. 1998 Oct;19(10):424-30 [9803833.001]
  • [Cites] Leuk Lymphoma. 1998 Oct;31(3-4):405-9 [9869205.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45270-5 [11584005.001]
  • [Cites] Hematol Oncol. 2001 Dec;19(4):151-7 [11754391.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):3-9 [11790973.001]
  • [Cites] Leuk Res. 2002 Jul;26(7):621-9 [12008078.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):860-8 [12060121.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]
  • [Cites] Mol Cancer Ther. 2002 Apr;1(6):371-6 [12477049.001]
  • [Cites] Cancer Treat Res. 2002;112:27-47 [12481710.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):761-70 [10353709.001]
  • (PMID = 16333246.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Equilibrative Nucleoside Transporter 1; 0 / RNA, Messenger; 0 / SLC29A1 protein, human; 04079A1RDZ / Cytarabine
  • [Other-IDs] NLM/ PMC2361532
  •  go-up   go-down


34. Hiçsönmez G, Cetin M, Okur H, Erdemli E, Gürgey A: The potential effect of short-course high-dose steroid on the maturation and apoptosis of leukemic cells in a child with acute megakaryoblastic leukemia. Leuk Lymphoma; 2003 Jun;44(6):1037-42
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential effect of short-course high-dose steroid on the maturation and apoptosis of leukemic cells in a child with acute megakaryoblastic leukemia.
  • High-dose methylprednisolone (HDMP) treatment has been shown to induce differentiation of myeloid leukemic cells in children with acute promyelocytic leukemia and other subtypes (FAB AML M1-M2-M4) of acute myeloblastic leukemia.
  • In the present study, a child with acute megakaryoblastic leukemia (AMKL) was given HDMP (30 mg/kg/day) orally in a single dose for the first 4 days of induction therapy.
  • A marked decrease in peripheral blood blast cells and an increase in platelet count associated with a striking change in bone marrow (BM) morphology was observed following a short-course of HDMP treatment alone.
  • BM cells developed distinct morphology characterized by cytoplasmic blebbing and some appeared as platelet producing micromegakaryocytes.
  • Flow cytometric analysis of the BM cells 4 days after HDMP treatment demonstrated a decrease in the percentage of cells co-expressing CD34 and CD117 antigens and a marked increase in CD42a antigen.
  • These changes in BM morphology and immunophenotype may suggest maturation effect of HDMP on megakaryocytic leukemic cells.
  • This was coincident with a significant increase in the percentage of annexin positive cells.
  • These results suggest that HDMP treatment may induce differentiation and apoptosis of leukemic cells in a child with AMKL and it could be a promising agent for remission induction of patients with AMKL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / pathology. Methylprednisolone / therapeutic use
  • [MeSH-minor] Bone Marrow Cells / drug effects. Bone Marrow Cells / pathology. Child, Preschool. Cytarabine / administration & dosage. Flow Cytometry. Humans. Male. Mitoxantrone / administration & dosage. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12854906.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


35. Fujii S, Miyata A, Kikuchi T, Kibata M: [An elderly case of acute myelocytic leukemia complicated with bleeding gastric angiodysplasia, successfully treated with topical endoscopic polidocanol injection]. Nihon Ronen Igakkai Zasshi; 2004 May;41(3):334-8
Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly case of acute myelocytic leukemia complicated with bleeding gastric angiodysplasia, successfully treated with topical endoscopic polidocanol injection].
  • A 72-year-old man with acute myelocytic leukemia (AML) suffered relapsing massive bleeding from gastric angiodysplasia.
  • He had hypercellular (nucleated cell count 42 x 10(4)/microl) bone marrow with 90% myeloblasts, and AML (FAB: M1) was diagnosed.
  • Remission induction therapy by BHAC/DM regimen failed.
  • While considering subsequent regimens, massive hematemesis from a solitary gastric angiodysplasia developed.
  • After achievement of complete remission by CAG therapy, he was treated on an outpatient basis.
  • In July, his AML relapsed and he was treated mainly by transfusion therapy.
  • In September, hematemesis recurred resulting in hemostasis with the same procedure.
  • In this case, topical injection of polidocanol was an effective procedure for the massive bleeding from it even in an elderly patient with the complication of thrombocytopenia due to AML.
  • [MeSH-major] Angiodysplasia / complications. Gastrointestinal Hemorrhage / drug therapy. Leukemia, Myeloid, Acute / complications. Polyethylene Glycols / administration & dosage. Stomach Diseases / complications


36. Srivastava MD, Ambrus JL: Effect of 1,25(OH)2 Vitamin D3 analogs on differentiation induction and cytokine modulation in blasts from acute myeloid leukemia patients. Leuk Lymphoma; 2004 Oct;45(10):2119-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 1,25(OH)2 Vitamin D3 analogs on differentiation induction and cytokine modulation in blasts from acute myeloid leukemia patients.
  • In acute myeloid leukemia (AML), cell proliferation and differentiation are uncoupled, causing a maturation block.
  • Induction of terminal differentiation is a potential therapeutic strategy.
  • We investigated 1alpha, 25(OH)2 Vitamin D3 and 5 of its more potent analogs with reduced calcium resorbing activity for differentiation of blast cells from AML (FAB M1) patients, compared to TPA.
  • Vitamin D3 and its analogs can induce differentiation of primary cells from AML patients in vitro, but may need to be combined with other agents for terminal differentiation of blasts and effective therapy in vivo.
  • [MeSH-major] Calcitriol / analogs & derivatives. Cell Differentiation / drug effects. Cytokines / antagonists & inhibitors. Granulocyte Precursor Cells / drug effects. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Acute Disease. Cell Adhesion. Cells, Cultured. Dose-Response Relationship, Drug. Humans. Interleukin-6 / antagonists & inhibitors. Interleukin-8 / antagonists & inhibitors. Structure-Activity Relationship

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15370259.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Interleukin-8; FXC9231JVH / Calcitriol
  •  go-up   go-down


37. Chelghoum Y, Danaïla C, Belhabri A, Charrin C, Le QH, Michallet M, Fiere D, Thomas X: Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. Ann Oncol; 2002 Oct;13(10):1621-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of cigarette smoking on the presentation and course of acute myeloid leukemia.
  • BACKGROUND: It is known that cigarette smoking is associated with an approximately 50% increase in leukemia risk.
  • In order to detect a possible influence of cigarette smoking on initial characteristics at the time of presentation and on the course of the disease, we conducted a retrospective study in 643 patients with newly diagnosed acute myeloid leukemia.
  • RESULTS: Cigarette smoking was significantly related to male gender (P <0.0001), professional occupancy (P = 0.002), presence of organomegaly (P = 0.01), and lower peripheral blood and bone marrow leukemic cell involvement (P = 0.007 and P = 0.0001, respectively).
  • Leukemia of French-American-British (FAB) M1 subtype was more frequent in non-smokers (P = 0.005).
  • However, a higher rate of severe pulmonary infection was observed in smokers during induction chemotherapy (P = 0.02).
  • Other characteristics associated with poor prognosis included mainly older age, unfavorable karyotype, secondary acute myeloid leukemia (AML) and elevated World Health Organization (WHO) performance status.
  • CONCLUSIONS: Cigarette smoking has a deleterious effect on survival in AML by shortening complete remission duration and subsequent survival.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Smoking and Youth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377652.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Skladanowski A, Bozko P, Sabisz M, Larsen AK: Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy. Cell Cycle; 2007 Sep 15;6(18):2268-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling: implications for cancer therapy.
  • Natural (intrinsic) resistance of many tumor types to DNA damaging agents is closely associated with their capacity to undergo robust cell cycle arrest in G(2)/M.
  • G(2) arrest is regulated by the DNA damage checkpoint and by survival signaling, with a potential role of PI3K/Akt in checkpoint function.
  • We compared the influence of UCN-01, which affects both the DNA damage checkpoint and PI3K/Akt-mediated survival signaling, with the PI3K inhibitors wortmannin and LY294002 in p53-deficient M1 acute myeloid leukemia cells treated with the DNA damaging agent cisplatin.
  • Unexpectedly, dual inhibition of both survival and checkpoint signaling by UCN-01, also increased the cytotoxicity of cisplatin, but to a lesser degree than wortmannin or LY294002.
  • Our results elucidate a novel function for PI3K/Akt as a survival factor during DNA damage-induced G(2) arrest and could have important pharmacological consequences for the application of response modulators in p53-deficient tumors with strong survival signaling.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA Damage / physiology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Signal Transduction / physiology. Tumor Suppressor Protein p53 / deficiency
  • [MeSH-minor] Animals. Cell Cycle / drug effects. Cell Cycle / physiology. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Cell Survival / physiology. Mice. Neoplasms / drug therapy. Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17890906.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


39. Lo Nigro L, Schiliro G: Occurrence of a FAB-M1 AML in a child during treatment of APL: emergence of an immature clone or a therapy related-AML? Haematologica; 2002 May;87(5):ELT26
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of a FAB-M1 AML in a child during treatment of APL: emergence of an immature clone or a therapy related-AML?
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Fatal Outcome. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12010686.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating
  •  go-up   go-down


40. Takahashi T, Maruyama Y, Satoh Y, Yoshimoto M, Tsujisaki M: Complex t(8;14;21)(q22;q13;q22), a variant of t(8;21), with t(15;21)(q15;p11) in a patient with acute myelogenous leukemia (M1). Cancer Genet Cytogenet; 2004 Dec;155(2):152-3
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex t(8;14;21)(q22;q13;q22), a variant of t(8;21), with t(15;21)(q15;p11) in a patient with acute myelogenous leukemia (M1).
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 15. Chromosomes, Human, Pair 21. Chromosomes, Human, Pair 8. Genetic Variation. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / prevention & control. Translocation, Genetic
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Core Binding Factor Alpha 2 Subunit. Cytarabine / therapeutic use. Drug Therapy, Combination. Female. Humans. Idarubicin / therapeutic use. Karyotyping. Leukocytes, Mononuclear / chemistry. Middle Aged. Oncogene Proteins, Fusion / genetics. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Secondary Prevention. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15571802.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Antimetabolites, Antineoplastic; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Transcription Factors; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down






Advertisement